



**University of  
Zurich<sup>UZH</sup>**

**Zurich Open Repository and  
Archive**

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2019

---

## **Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection**

Kountouras, Jannis ; Doulberis, Michael ; Papaefthymiou, Apostolis ; Polyzos, Stergios A ; Touloumtzi, Maria ; Elisabeth, Vardaka ; Kapetanakis, Nikolaos ; Liatsos, Christos ; Gavalas, Emmanouel ; Katsinelos, Panagiotis

DOI: <https://doi.org/10.1007/s00018-019-03106-4>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-181167>

Journal Article

Accepted Version

Originally published at:

Kountouras, Jannis; Doulberis, Michael; Papaefthymiou, Apostolis; Polyzos, Stergios A; Touloumtzi, Maria; Elisabeth, Vardaka; Kapetanakis, Nikolaos; Liatsos, Christos; Gavalas, Emmanouel; Katsinelos, Panagiotis (2019). Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double-edged sword reflection. Cellular and Molecular Life Sciences, 76(13):2487-2488.

DOI: <https://doi.org/10.1007/s00018-019-03106-4>

# **Helicobacter pylori infection and gastrointestinal tract cancer biology: considering a double- edged sword reflection**

**Jannis Kountouras, MD, PhD<sup>1</sup>, Michael Doulberis, MD, DVM, PhD<sup>1,2</sup>, Apostolis Papaefthymiou, MD<sup>1</sup>, Stergios A. Polyzos, MD, Msc, PhD<sup>3</sup>, Maria Touloumtzi, MD<sup>1</sup>, Vardaka Elisabeth, PhD<sup>1</sup>, Nikolaos Kapetanakis, MD, PhD<sup>1</sup>, Christos Liatsos MD, PhD<sup>1</sup> Emmanouel Gavalas, MD, PhD<sup>1</sup>, Panagiotis Katsinelos, MD, PhD<sup>1</sup>**

<sup>1</sup>Department of Medicine, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki 54642, Macedonia, Greece

<sup>2</sup>Department of Gastroenterology and Hepatology, University of Zurich, Zurich 8091, Switzerland

<sup>3</sup>First Department of Pharmacology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Macedonia, Greece

**Key words:** *Helicobacter pylori*; gastrointestinal cancer; bone marrow-derived stem cell; microbiota; dysbiosis

**Financial support:** None

**Potential competing interests:** None

Please address correspondence to:

Jannis Kountouras, MD, PhD

Professor of Medicine

8 Fanariou St, Byzantio

551 33, Thessaloniki, Macedonia

Greece

Tel: +30-2310-892238, Fax: +30-2310-992794

E-mail: jannis@auth.gr, ancoratus2010@gmail.com

Dear Editor,

In their comprehensive review Mentis et al. [1] discussed some molecular biological mechanisms involved in *Helicobacter pylori* infection (*Hp*-I)-related gastric cancer (GC) biology such as the role of stem cells and the link between *Hp*-I and gastrointestinal microbiota (GI-M). Moreover, they posed some «unsolved conundrums» such as the following: *Hp*-I induces gastric and duodenal inflammation, but is only linked to GC. This claim, however, is incomplete, because *Hp*-I is also linked with duodenal adenomas/carcinomas [2]. Moreover, *Hp*-I induces lower GI tract inflammation, thereby promoting oncogenesis [3,4]. In this regard, we wish to add some additional data involving *Hp*-I in upper and lower GI tract oncogenesis.

Concerning the role of stem cells in *Hp*-I-related GC, we earlier reviewed [5] mechanisms of *Hp* and stem cell interaction in GC such as: activation of the Wnt/ $\beta$ -catenin signaling pathway; CagA impact on the fibroblast growth factor signal pathways implicated in the development of GC; enhancing transforming growth factor- $\beta$ /bone morphogenetic proteins signal pathway involved in GC cells invasion; sonic hedgehog signaling dysregulation; and recruitment of mesenchymal stem cells and/or bone marrow-derived stem cells (BMDSCs), also mentioned in one original study (2004) by the authors [1], in the course of chronic inflammatory condition, that gains stepwise transformation to GC cells [5]. Likewise, such aforementioned mechanisms have been confirmed by more recent data [6], further indicated that *Hp*-I activates epithelial-mesenchymal transition pathway and induces the development of GC stem cells (CSCs), such as CD44(+) [7]. Regarding the latter aspect, by using CSC and/or BMDSCs marker CD44, the CD44(+) gastric CSCs appear to display the stem cell self-renewal properties. Moreover, *Hp* is responsible for CD44(+) increased expression, indicating a potential *Hp* induction of CD44(+) gastric CSCs implicated in gastric tumorigenesis [3]. Furthermore, our studies showed presence of cyclin D1 involved in GC cell proliferation, as well as CD34 expressed on hematopoietic stem cells and neovessels in human *Hp*-related GC specimens [8]. Beyond GC, our studies also showed CD44(+) augmented expression in human *Hp*-connected colorectal adenoma (CRA) and colorectal cancer (CRC) tissues [3]. Therefore, *Hp*-I could have an impact on colon oncogenesis by stimulating CSCs or recruiting BMDSCs, similar to upper GI *Hp*-I-connected chronic inflammation-metaplasia-dysplasia sequence and BMDSCs recruitment that contribute to oncogenesis [3]. Thus further large-scale relative studies are warranted.

BMDSCs might also contribute to the pathogenesis of Barrett's esophagus (BE) [9], a complication of gastroesophageal reflux disease (GERD), which predisposes to BE-related esophageal adenocarcinoma (EAC) development. In this concern, it has been proposed that chronic *Hp*-I induces atrophic gastritis accompanying by decreased acid secretion and acid reflux, thereby reducing the risk of GERD and its related BE and EAC. However, this conventional consideration might represent a

double- edged sword one view. Regarding the opposed view, the authors reported that *Hp*-I influences the GI-M composition including the presence of gastric species such as *Campylobacter* [1]. Hypochlorhydria induced by *Hp*-related atrophic gastritis, results in GI-M dysbiosis, which, beyond GC, could also contribute to BE-EAC sequence [10,11]. In this regard, *Campylobacter*, as main influential genera in *Hp*-connected atrophic gastritis specimens, and gastric atrophy-induced GM could contribute to gastric carcinogenesis [10]. Equally, data on BE biofilm show high atypical nitrate reducing *Campylobacter* species in BE which, via chronic inflammation, may contribute to the development of BE and/or its progression to EAC [11]. Therefore, *Hp*-induced *Campylobacter* species and dysbiosis, through chronic esophageal inflammation may lead to EAC development [11,12] and thus further investigation is needed.

Concerning the role of molecular events involved in *Hp*-I-related GERD-BE-EAC sequence, we also summarized [13] *Hp* relative pathogenic mechanisms such as: *Hp* induction of GI tract oncogenic gastrin, which stimulates Barrett's EAC cells proliferation via Janus Kinase (JAK)2 and Akt-dependent nuclear factor-kappa B (NF- $\kappa$ B) activation, displays a anti-apoptotic effect through Bcl-2 protein and survivin upregulation, and induces the mitogenic cyclooxygenase (COX)-2 expression that contributes to GI tract carcinogenesis. Specifically, COX-2 derived prostaglandins (PGs) contribute to BE-associated cancer progression, by perpetuating chronic inflammation. Likewise, the PGs mitogenic and antiapoptotic properties are mediated through activation of certain aforementioned signaling pathways including NF- $\kappa$ B, Sarcoma family protein tyrosine (Src), JAK2/Signal transducers and activators of transcription (STAT)3, Extracellular-signal Regulated (ERK), mitogen-activated protein (MARK) and phosphoinositide-3-kinase–protein kinase B (PI3K/Akt) kinases. Moreover, *Hp*-I could provoke specific molecular changes (genetic instability, E-cadherin methylation, monoclonal antibody Das-1) linked with BE pathophysiology, and promotes Ki-67 expression predicting BE malignant progression. Finally, *Hp*-related metabolic syndrome disorders associated with GI-M dysbiosis also appear to be involved in GI tract carcinogenesis [13-15]. Therefore, *Hp* eradication might inhibit aforementioned oncogenic processes, and thus further studies are necessary.

## References

1. Mentis AA, Boziki M, Grigoriadis N, Papavassiliou AG ( 2019) *Helicobacter pylori* infection and gastric cancer biology: tempering a double-edged sword. Cell Mol Life Sci Feb 19. doi: 10.1007/s00018-019-03044-1. [Epub ahead of print]
2. Maruoka D, Arai M, Ishigami H, et al (2015) Sporadic nonampullary duodenal adenoma/carcinoma is associated with not only colon adenoma/carcinoma but also gastric cancer: association of location of duodenal lesions with comorbid diseases. Scand J Gastroenterol 50:333-340.

3. Kapetanakis N, Kountouras J, Zavos C et al (2013) Association of *Helicobacter pylori* infection with colorectal cancer. *Immunogastroenterology* 2:47–56.
4. Butt J, Varga MG, Blot WJ, et al (2019) Serologic Response to *Helicobacter pylori* Proteins Associated With Risk of Colorectal Cancer Among Diverse Populations in the United States. *Gastroenterology* 156:175-186.
5. Pilpilidis I, Kountouras J, Zavos C, Katsinelos P (2011) Upper gastrointestinal carcinogenesis: *H. pylori* and stem cell cross-talk. *J Surg Res* 166:255-64.
6. Kim N (2019) Chemoprevention of gastric cancer by *Helicobacter pylori* eradication and its underlying mechanism. *J Gastroenterol Hepatol* Mar 3. doi: 10.1111/jgh.14646. [Epub ahead of print]
7. Choi YJ, Kim N, Chang H, et al (2015) *Helicobacter pylori*-induced epithelial-mesenchymal transition, a potential role of gastric cancer initiation and an emergence of stem cells. *Carcinogenesis* 36: 553–63.
8. Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P (2008) New aspects of *Helicobacter pylori* infection involvement in gastric oncogenesis. *J Surg Res* 146:149-58.
9. Hutchinson L, Stenstrom B, Chen D, et al (2011) Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. *Stem Cells Dev* 20:11-7.
10. Parsons BN, Ijaz UZ, D'Amore R, et al (2017) Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of *Helicobacter pylori*-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. *PLoS Pathog* 13: e1006653.
11. Mozaffari Namin B, Soltan Dallal MM, Ebrahimi Daryani N (2015) The Effect of *Campylobacter concisus* on Expression of IL-18, TNF- $\alpha$  and p53 in Barrett's Cell Lines. *Jundishapur J Microbiol* 8:e26393.
12. Yang L, Chaudhary N, Baghdadi J, Pei Z (2014) Microbiome in reflux disorders and esophageal adenocarcinoma. *Cancer J* 20:207-10.
13. Kountouras J, Polyzos SA, Doulberis M, et al (2018) Potential impact of *Helicobacter pylori*-related metabolic syndrome on upper and lower gastrointestinal tract oncogenesis. *Metabolism* 87:18-24.
14. Lin XH, Huang KH, Chuang WH, et al (2018) The long term effect of metabolic profile and microbiota status in early gastric cancer patients after subtotal gastrectomy. *PLoS One* 13:e0206930.
15. Qin Y, Roberts JD, Grimm SA, et al (2018) An obesity-associated gut microbiome reprograms the intestinal epigenome and leads to altered colonic gene expression. *Genome Biol* 19:7.